Market research
ARCH.V Arch Biopartners Inc
V CAD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 59M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.8
Profile
Instrument facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA03938C1041
- Market cap
- 59M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.8
About
About Arch Biopartners Inc
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.
Research context
Arch Biopartners Inc appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ARCH.V discussion.
5 years, 6 months ago
Arch Biopartners Inc is currently in a long term downtrend where the price is trading 4.9% below its 200 day moving average.
From a valuation standpoint, the stock is 15.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1182.1.
Arch Biopartners Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 125.4% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 48.8% to $-710K since the same quarter in the previous year.
Based on the above factors, Arch Biopartners Inc gets an overall score of 0/5.